°¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ¼±µµÇü ¸é¿ªÁúȯÀ¶ÇÕ¿¬±¸»ç¾÷´Ü(´ÜÀå : ½ÅÀå³»°ú ¾çö¿ì ±³¼ö)ÀÌ ¼¿ï¼º¸ðº´¿ø °¡Å縯Á¶Ç÷¸ð¼¼Æ÷ÀºÇà ¹× Àå±âÀ̽Ŀ¬±¸¼Ò¿Í ÇÔ²² 7¿ù 12ÀÏ ½¦¶óÅæ ÆÈ·¡½º °³² È£ÅÚ ±×·£µåº¼·ë¿¡¼ Á¶Á÷ÀûÇÕ¼ºÇ׿ø(Human Leukocyte Antigen, HLA)°Ë»ç¿¡ ´ëÇÑ ÃֽŠÁö°ßÀ» °øÀ¯ÇÏ´Â 'HLA SYMPOSIUM'À» °³ÃÖÇß´Ù.
Á¶Á÷ÀûÇÕ°Ë»ç¹ýÀº ¼º°øÀûÀÎ Àå±âÀ̽İú Á¶Ç÷¸ð¼¼Æ÷À̽ÄÀ» À§ÇÑ ÇʼöÀû ¸é¿ª°Ë»çÀ̳ª, ¾ÆÁ÷ ÇØ°áµÇÁö ¸øÇÑ ¸¹Àº ºÎºÐµéÀ» ÇØ°áÇϱâ À§ÇÑ ¹æÇâ ¼³Á¤À¸·Î Â÷¼¼´ë¿°±â¼¿ºÐ¼®¹ý(NGS)À» ÀÌ¿ëÇÑ Á¶Á÷ÀûÇÕ°Ë»ç¹ý¿¡ ÃÊÁ¡À» µÎ¾î À̹ø Çà»ç¸¦ ÁøÇàÇÏ¿´´Ù.
À̳¯ ½ÉÆ÷Áö¿òÀº ¢º Clinical importance of HLA typing : ±èÈñÁ¦ ±³¼ö(¼¿ï¼º¸ðº´¿ø), Çã±ÔÇÏ ±³¼ö(¼¼ºê¶õ½º º´¿ø) ¢º Application of NGS : ±èÅÂ±Ô ±³¼ö(°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ), ±è¿ë±¸ ±³¼ö(¼¿ï¼º¸ðº´¿ø)ÀÇ ÃÑ 2°¡Áö ¼¼¼ÇÀ¸·Î ±¸¼ºµÇ¾î Àå±âÀÌ½Ä ¹× Á¶Ç÷¸ð¼¼Æ÷À̽Ŀ¡¼ Á¶Á÷ÀûÇÕ¼ºÇ׿ø(HLA)°Ë»çÀÇ ÀÓ»óÀû Á߿伺 ¹× Á¶Ç÷¸ð¼¼Æ÷ ±âÁõ Èñ¸ÁÀÚÀÇ Á¶Á÷ÀûÇÕ¼ºÇ׿ø¿¡ ´ëÇÑ Â÷¼¼´ë¿°±â¼¿ºÐ¼®¹ý(Next Generation Sequencing, NGS)À» ¼Ò°³ÇÏ´Â ³»¿ëÀ¸·Î ÁøÇàµÇ¾ú´Ù.
´õºÒ¾î »ç¾÷´ÜÀÇ ±èÅÂ±Ô ±³¼ö´Â ÀÚü °³¹ßÇÑ Â÷¼¼´ë¿°±â¼¿ºÐ¼®¹ýÀ» ÅëÇÑ Á¶Á÷ÀûÇÕ¼ºÇ׿ø °Ë»ç¹ýÀ» ÀÌ¿ëÇÏ¿© Á¶Ç÷¸ð¼¼Æ÷ ±âÁõÈñ¸ÁÀÚ 2¸¸¿© ¸íÀÇ °Ë»ç°á°ú¸¦ ¹ßÇ¥ÇÏ¿´°í, ÀÌ ¿¬±¸°á°ú´Â ±×µ¿¾È ÇØ¿Ü¿¡ 100% ÀÇÁ¸ÇÏ´ø ¸é¿ª°Ë»ç¹ýÀÇ ±¹»êÈ ±âƲÀ» ¸¶·ÃÇÏ¿´´Ù´Â Á¡¿¡¼ ÀÇÀÇ°¡ Å©´Ù.
¾çö¿ì ¼±µµÇü ¸é¿ªÁúȯÀ¶ÇÕ¿¬±¸»ç¾÷´ÜÀåÀº ¡°À̹ø HLA ½ÉÆ÷Áö¾öÀ» ÅëÇØ ¼¿ï¼º¸ðº´¿øÀÌ Àå±âÀÌ½Ä ¹× Á¶Ç÷¸ð¼¼Æ÷À̽ÄÀÇ ¼±µµ º´¿øÀ¸·Î½á ºê·£µå °¡Ä¡¸¦ ´õ¿í »ó½Â½ÃÅ°°í, ±Ã±ØÀûÀ¸·Î °íÅë ¹Þ´Â È¯¿ìµé¿¡°Ô µµ¿òÀÌ µÇ´Â °è±â°¡ µÉ °Í¡±À̶ó°í ¹àÇû´Ù.